PEACE-3 Study ESMO 2024 - Combining Enzalutamide + Radium-223 in mCRPC

we discussed two important studies in prostate cancer. The first was the PEACE-3 trial, which evaluated the combination of enzalutamide and radium-223, showing improved radiographic progression-free survival. However, Dr. Grivas pointed out the challenges in applying these findings to modern patient populations who often have prior exposure to novel antiandrogens.

Tune in for an insightful discussion that highlights the latest advancements in GU cancer treatment and their potential impact on clinical practice. Don't forget to check out our other episodes covering breast cancer, lung cancer, and GI malignancies from ESMO 2024!

#oncologybrothers #oncology #breastcancer #CancerResearch #PEACE-3 #Enzalutamide #mCRPC